161 related articles for article (PubMed ID: 21848481)
1. Candesartan in the treatment of hypertension: what have we learnt in the last decade?
Barrios V; Escobar C
Expert Opin Drug Saf; 2011 Nov; 10(6):957-68. PubMed ID: 21848481
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and tolerability of candesartan cilexetil in special patient groups.
Trenkwalder P
Blood Press Suppl; 2000; 1():27-30. PubMed ID: 11059633
[TBL] [Abstract][Full Text] [Related]
3. Candesartan cilexetil--a review of effects on cardiovascular complications in hypertension and chronic heart failure.
Meredith PA
Curr Med Res Opin; 2007 Jul; 23(7):1693-705. PubMed ID: 17588300
[TBL] [Abstract][Full Text] [Related]
4. Improving antihypertensive efficacy while maintaining placebo-like tolerability.
Sever PS
Blood Press Suppl; 2000; 1():19-22. PubMed ID: 11059631
[TBL] [Abstract][Full Text] [Related]
5. [Change from ACE inhibitor, Ca-antagonist or beta-blocker to candesartan cilexetil: better efficacy and tolerance. SWITCH study (German study segment)].
Baumgart P; Reismann J; Pohlmeyer H; Düsing R
Dtsch Med Wochenschr; 2001 May; 126(19):547-50. PubMed ID: 11402910
[TBL] [Abstract][Full Text] [Related]
6. Candesartan plus hydrochlorothiazide: an overview of its use and efficacy.
Mugellini A; Nieswandt V
Expert Opin Pharmacother; 2012 Dec; 13(18):2699-709. PubMed ID: 23170938
[TBL] [Abstract][Full Text] [Related]
7. Candesartan cilexetil: a new, long-acting, effective angiotensin II type 1 receptor blocker.
Sever P
J Hum Hypertens; 1997 Sep; 11 Suppl 2():S91-5. PubMed ID: 9331018
[TBL] [Abstract][Full Text] [Related]
8. Candesartan cilexetil: in children and adolescents aged 1 to <17 years with hypertension.
Hoy SM; Keating GM
Am J Cardiovasc Drugs; 2010; 10(5):335-42. PubMed ID: 20860416
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of the efficacy and tolerability of combination therapy with candesartan cilexetil and amlodipine besilate compared with candesartan cilexetil monotherapy and amlodipine besilate monotherapy in Japanese patients with mild-to-moderate essential hypertension: a multicenter, 12-week, randomized, double-blind, placebo-controlled, parallel-group study.
Rakugi H; Ogihara T; Miyata Y; Sasai K; Totsuka N
Clin Ther; 2012 Apr; 34(4):838-48. PubMed ID: 22440192
[TBL] [Abstract][Full Text] [Related]
10. Preserving target-organ function with candesartan cilexetil in patients with hypertension.
Zannad F
Blood Press Suppl; 2000; 1():36-9. PubMed ID: 11059635
[TBL] [Abstract][Full Text] [Related]
11. A placebo-controlled comparison of the efficacy and tolerability of candesartan cilexetil, 8 mg, and losartan, 50 mg, as monotherapy in patients with essential hypertension, using 36-h ambulatory blood pressure monitoring.
Baguet JP; Nisse-Durgeat S; Mouret S; Asmar R; Mallion JM
Int J Clin Pract; 2006 Apr; 60(4):391-8. PubMed ID: 16620350
[TBL] [Abstract][Full Text] [Related]
12. Switch from ABCD pretreatment to A-II-A treatment: a multinational, open, centrally randomized, prospective parallel group comparison.
Asmar R; Porcellati C; Dusing R
Drugs Exp Clin Res; 2004; 30(4):153-61. PubMed ID: 15553661
[TBL] [Abstract][Full Text] [Related]
13. Improving prognosis in hypertension: exploring the benefits of angiotensin II type 1 receptor blockade.
Ruilope L
Blood Press Suppl; 2000; 1():31-5. PubMed ID: 11059634
[TBL] [Abstract][Full Text] [Related]
14. The efficacy and tolerability of candesartan cilexetil in an elderly hypertensive population.
McInnes GT; O'Kane KP; Jonker J; Roth J
J Hum Hypertens; 1997 Sep; 11 Suppl 2():S75-80. PubMed ID: 9331015
[TBL] [Abstract][Full Text] [Related]
15. Candesartan cilexetil effectively reduces blood pressure in hypertensive children.
Franks AM; O'Brien CE; Stowe CD; Wells TG; Gardner SF
Ann Pharmacother; 2008 Oct; 42(10):1388-95. PubMed ID: 18664605
[TBL] [Abstract][Full Text] [Related]
16. Clinical profile of the novel angiotensin II type I blocker candesartan cilexetil.
Sever PS
J Hypertens Suppl; 1997 Dec; 15(6):S9-12. PubMed ID: 9493121
[TBL] [Abstract][Full Text] [Related]
17. [Investigations of the antihypertensive long-term action of candesartan cilexetil in different dosages under the influence of therapy-free intervals].
Weisser B; Gerwe M; Braun M; Funken C
Arzneimittelforschung; 2005; 55(9):505-13. PubMed ID: 16229114
[TBL] [Abstract][Full Text] [Related]
18. Long-acting blood pressure reduction by candesartan cilexetil in patients with hypertension.
Bönner G; Fuchs W
Curr Med Res Opin; 2005 Jun; 21(6):935-40. PubMed ID: 15969893
[TBL] [Abstract][Full Text] [Related]
19. Candesartan cilexetil and enalapril are of equivalent efficacy in patients with mild to moderate hypertension.
Zanchetti A; Omboni S; Di Biagio C
J Hum Hypertens; 1997 Sep; 11 Suppl 2():S57-9. PubMed ID: 9331009
[No Abstract] [Full Text] [Related]
20. Long-term efficacy and tolerability of candesartan cilexetil in patients with mild to moderate hypertension.
Sever P; Holzgreve H
J Hum Hypertens; 1997 Sep; 11 Suppl 2():S69-73. PubMed ID: 9331014
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
